Skip to main content

Cerebral Small Vessel Diseases

2
Pipeline Programs
4
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Tasly Pharmaceutical
Tasly PharmaceuticalChina - Tianjin
1 program
1
Cerebralcare pillsPhase 41 trial
Active Trials
NCT05578521Unknown114Est. Mar 2024
Nordic Pharma
Nordic PharmaFrance - Paris
1 program
1
Tadalafil 20 MGPhase 21 trial
Active Trials
NCT05173896Active Not Recruiting100Est. Dec 2029
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
Butylphthalide Soft CapsulesN/A1 trial
Active Trials
NCT04078204Unknown300Est. Jun 2022
Integrated Biosciences
Integrated BiosciencesCA - San Carlos
1 program
data collection and follow-upN/A1 trial
Active Trials
NCT05985213Recruiting1,078Est. Dec 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Tasly PharmaceuticalCerebralcare pills
Nordic PharmaTadalafil 20 MG
Integrated Biosciencesdata collection and follow-up
UNION therapeuticsButylphthalide Soft Capsules

Clinical Trials (4)

Total enrollment: 1,592 patients across 4 trials

NCT05578521Tasly PharmaceuticalCerebralcare pills

CerebrAlcare Pills on CereBral Small VesseL DiseasE（CABLE）

Start: Jun 2022Est. completion: Mar 2024114 patients
Phase 4Unknown
NCT05173896Nordic PharmaTadalafil 20 MG

Improving Cerebral Blood Flow and Cognition in Patients with Cerebral Small Vessel Disease. the ETLAS-2 Trial

Start: May 2022Est. completion: Dec 2029100 patients
Phase 2Active Not Recruiting
NCT05985213Integrated Biosciencesdata collection and follow-up

Cohort Study of Inpatients and Outpatient Patients With Cerebral Small Vessel Disease

Start: Dec 2020Est. completion: Dec 20281,078 patients
N/ARecruiting
NCT04078204UNION therapeuticsButylphthalide Soft Capsules

A Clinical Study on the Treatment of Cerebral Small Vascular Disease

Start: Apr 2018Est. completion: Jun 2022300 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,592 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.